Daily Roundup

SS1.ASX MCE.ASX AZY.ASX AYA.ASX TLX.ASX

Sun Silver Ltd Requests Trading Halt

Sun Silver Ltd has requested an immediate trading halt on its ordinary shares, pending the release of an announcement regarding a Mineral Resource upgrade. The trading halt is expected to remain in place until the earlier of the announcement release and the commencement of trading on 10 December 2025. The company has stated that it is not aware of any reason why the trading halt should not be granted.

Matrix Composites Redeems $7.5M Convertible Note

Matrix Composites & Engineering Ltd has announced the redemption of its $7.5 million convertible note that matured on 5 December 2025. The repayment was funded via a new $7.5 million term loan, which is part of the recently announced facility agreement with National Australia Bank (NAB). This means Matrix's net debt position will not be impacted by the redemption. The new debt facilities with NAB deliver improved size and pricing compared to the convertible note structure and have a 3-year tenor maturing in November 2028.

Discoveries at RPS and Minyari Depth Target Confirmed

Antipa Minerals Ltd has reported excellent exploration results from its Minyari Gold-Copper Project, including high-grade intersections beneath the existing Minyari Dome Deposit, continued down dip extensions at Fiama, and multiple thick gold-copper-silver intersections at the emerging Reaper-Poblano-Serrano (RPS) target. The Phase 2 CY2025 Exploration Drilling Programme is now complete, with an updated Mineral Resource Estimate on track for release prior to year-end. Follow-up drilling is planned for Q2 CY2026 to test the continuity and extent of mineralization at RPS and Tim's Dome.

Artrya Secures Second US Commercial Customer

Artrya Limited has secured its second US commercial customer, signing a three-year agreement with Northeast Georgia Health System to use its Salix® AI-powered platform across the health system's network of hospitals and physician practices. The Salix® Coronary Anatomy platform will be licensed as a SaaS platform, while the Salix® Coronary Plaque module will generate fee-per-scan revenue. To support its growing US customer base and anticipated expansion, Artrya has established a Customer Success team in Atlanta.

First Patient Dosed in ProstACT Global Randomized Tx Expansion

Telix Pharmaceuticals Limited has announced that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 in patients with metastatic castration resistant prostate cancer. Part 2 of ProstACT Global will enroll approximately 490 patients and is currently recruiting patients in Australia, New Zealand and Canada, with plans to expand to the U.S. and Europe.